• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

The limits of DTC telehealth

Publication
Article
MHE PublicationMHE January 2021
Volume 31
Issue 1

Telehealth holds the promise of increasing access to care. But research findings concerning direct-to-consumer (DTC) telehealth, reported in JAMA Network Open last month, suggest that it might not be as simple as that.

Telehealth holds the promise of increasing access to care. But research findings concerning direct-to-consumer (DTC) telehealth, reported in JAMA Network Open last month, suggest that it might not be as simple as that.

Ateev Mehrotra, M.D., M.P.H., an associate professor of health policy and medicine at Harvard Medical School and a member of Managed Healthcare Executive®’s editorial advisory board, and Tara Jain, M.D., MBA, a physician at Brigham and Women’s Hospital in Boston, conducted a cross-sectional study of telehealth usage by using de-
identified data from a DTC telehealth company (they don’t name the company). The company’s services were available in 20 states, and the data Mehrotra and Jain used in the analysis were for about 35,000 visits between Oct. 1, 2019, and Dec. 31, 2019. Comparing the telehealth users with the overall population in those states, the researchers found that the telehealth patients were more likely to live in urban areas and high-income ZIP codes. Only 14.4% of the visits
were for patients living in areas identified as having a shortage
of primary care.

When Mehrotra and Jain looked at why people used the company’s services, they found that 87% of the visits were for one of three conditions: urinary tract infections (53%), erectile dysfunction (21%) and contraception (13%).

Mehrotra and Jain put barriers to access into different categories and suggest that their findings indicate that DTC telehealth helps with some barriers (accommodation barriers having to do with convenience and acceptability barriers having to do with embarrassment about sexual issues) but not others (clinician availability or affordability barriers). “Those seem like important barriers, and telehealth isn’t addressing them,” Mehrotra said.

But Mehrotra also stressed that “telehealth” is an umbrella term: “DTC is just one distinct form of telehealth,” he said. “In this application, the advantage was the convenience and avoidance of embarrassment. I think that is an important finding, but there are many other forms of telehealth.”

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.